Cascades Reports Solid Results for the Second Quarter of 2023

Author's Avatar
Aug 03, 2023

PR Newswire

Tissue Papers segment delivers strongest performance since 2020

KINGSEY FALLS, QC, Aug. 3, 2023 /PRNewswire/ - Cascades Inc. (TSX: CAS) reports its unaudited financial results for the three-month period ended June 30, 2023.

Q2 2023 Highlights

  • Sales of $1,168 million (compared with $1,134 million in Q1 2023 and $1,119 million in Q2 2022);
  • Operating income of $64 million (compared with an operating loss of $(80) million in Q1 2023 and operating income of $32 million in Q2 2022);
  • Net earnings per common share of $0.22 (compared with a net loss per common share of ($0.75) in Q1 2023 and net earnings per common share of $0.10 in Q2 2022);
  • Adjusted earnings before interest, taxes, depreciation and amortization (EBITDA (A)1) of $141 million (compared with $134 million in Q1 2023 and $91 million in Q2 2022);
  • Adjusted net earnings per common share1 of $0.27 (compared with adjusted net earnings per common share1 of $0.32 in Q1 2023 and adjusted net earnings per common share1 of $0.10 in Q2 2022);
  • Net debt1 of $2,076 million as of June 30, 2023 (compared with $2,070 million as of March 31, 2023). Net debt to EBITDA (A) ratio1 of 4.1x, down from 4.6x as of March 31, 2023;
  • Total capital expenditures, net of disposals, of $104 million in Q2 2023, compared to $137 million in Q1 2023 and to $116 million in Q2 2022. The Corporation's 2023 forecasted net capital expenditures of approximately $325 million is unchanged.

Mario Plourde, President and CEO, commented: "We had a solid second quarter, with consolidated sales and EBITDA (A)1 levels increasing 4% and 55%, respectively, year-over-year. Results were driven by the Tissue Papers segment, which had its strongest performance since Q2 2020, reflecting benefits from commercial and operational initiatives. The repositioning of our Tissue Papers platform announced at the end of April 2023 progressed as planned in the second quarter, with the closures completed as scheduled in June and July. We anticipate that these decisions, combined with the ongoing productivity optimization initiatives, which are also progressing as expected, will continue to strengthen the performance of our Tissue Papers business going forward. Slightly softer results in the Containerboard segment largely reflect lower index-linked selling prices, the effects of which more than offset the beneficial effect of lower raw material costs. As expected, Containerboard results include costs related to Bear Island as the facility continues to be ramped up. Lastly, results in the Specialty Packaging business decreased slightly year-over-year, as softer volumes and higher production costs more than offset higher selling prices."

Discussing near-term outlook, Mr. Plourde commented, "On a consolidated basis, we are expecting a stable operational performance sequentially in the third quarter, with the Containerboard and Specialty Packaging businesses generating stable results and the Tissue Papers segment delivering a slightly stronger performance. Additionally, we anticipate continued progress in the ramp up of the Bear Island Mill. More broadly, while we are remaining prudent on the demand-side, raw material pricing for our Tissue business and lower transportation costs for all of our businesses are expected to be tailwinds in the third quarter. Production cost levels are expected to be stable sequentially while continuing to be more elevated than last year. Lastly, we anticipate that our leverage ratio will continue to improve in the coming quarters.

We will be hosting a Bear Island Mill tour and institutional investor day in Virginia on September 14, 2023, and look forward to showcasing this modernized recycled containerboard facility and elaborating on our businesses and strategies to the financial community."

1 Some information represents non-IFRS financial measures, other financial measures or non-IFRS ratios which are not standardized under IFRS and therefore might not be comparable to similar financial measures disclosed by other corporations. Please refer to the "Supplemental Information on Non-IFRS Measures and Other Financial Measures" section for a complete reconciliation.


Financial Summary

Selected consolidated information

(in millions of Canadian dollars, except amounts per common share) (unaudited)

Q2 2023

Q1 2023

Q2 2022

Sales

1,168

1,134

1,119

As Reported

Operating income (loss)

64

(80)

32

Net income (loss)

22

(75)

10

per common share (basic)

$0.22

($0.75)

$0.10

Adjusted1

Earnings before interest, taxes, depreciation and amortization (EBITDA (A))

141

134

91

Net earnings

26

33

10

per common share (basic)

$0.27

$0.32

$0.10

Margin (EBITDA (A) / Sales)

12.1 %

11.8 %

8.1 %


Segmented sales

(in millions of Canadian dollars) (unaudited)

Q2 2023

Q1 2023

Q2 2022

Packaging Products

Containerboard

562

561

569

Specialty Products

164

161

168

Inter-segment sales

(9)

(7)

(10)

717

715

727

Tissue Papers

416

387

342

Inter-segment sales, Corporate, Recovery and Recycling activities

35

32

50

Sales

1,168

1,134

1,119


Segmented operating income (loss)

(in millions of Canadian dollars) (unaudited)

Q2 2023

Q1 2023

Q2 2022

Packaging Products

Containerboard

62

38

69

Specialty Products

19

21

20

Tissue Papers

18

(92)

(23)

Corporate, Recovery and Recycling activities

(35)

(47)

(34)

Operating income (loss)

64

(80)

32


Segmented EBITDA (A)1

(in millions of Canadian dollars) (unaudited)

Q2 2023

Q1 2023

Q2 2022

Packaging Products

Containerboard

96

126

99

Specialty Products

24

27

25

Tissue Papers

44

16

(8)

Corporate, Recovery and Recycling activities

(23)

(35)

(25)

EBITDA (A)1

141

134

91

1 Please refer to the "Supplemental Information on Non-IFRS Measures and Other Financial Measures" section for a complete reconciliation.


Analysis of results for the three-month period ended June 30, 2023 (compared to the same period last year)
The second quarter sales of $1,168 million increased by $49 million compared with the same period last year. This increase reflects a net benefit of $18 million that was driven by a beneficial impact from higher selling prices in Tissue Papers and Specialty Packaging, a favourable FX impact for all business segments, and higher volumes in Containerboard. These were partially offset by lower indexed selling prices in Containerboard and a lower contribution from Recovery and Recycling activities driven by recycled fibre material pricing changes.

The second quarter EBITDA (A)1 totaled $141 million, an increase of $50 million, or 55%, from the $91 million generated in the same period last year. This increase reflects stronger results in our Tissue Papers segment, the benefits of which were partially offset by slightly lower results in our Containerboard and Specialty Packaging businesses.

The main specific items, before income taxes, that impacted our second quarter 2023 operating income and/or net earnings were:

  • $2 million of impairment charges on US assets in the Tissue Papers segment (operating income and net earnings);
  • $6 million of restructuring costs related to the closure of Tissue Papers plants in the US (operating income and net earnings);
  • $1 million unrealized loss on financial instruments (operating income and net earnings);
  • $3 million foreign exchange gain on long-term debt and financial instruments (net earnings).

For the three-month period ended June 30, 2023, the Corporation posted net earnings of $22 million, or $0.22 per common share, compared to net earnings of $10 million, or $0.10 per common share, in the same period of 2022. On an adjusted basis1, the Corporation posted net earnings of $26 million in the second quarter of 2023, or $0.27 per common share, compared to net earnings of $10 million, or $0.10 per common share, in the same period of 2022.

1 Please refer to the "Supplemental Information on Non-IFRS Measures and Other Financial Measures" section for a complete reconciliation.


Dividend on common shares and normal course issuer bid
The Board of Directors of Cascades declared a quarterly dividend of $0.12 per common share to be paid on September 1, 2023 to shareholders of record at the close of business on August 18, 2023. This dividend is an "eligible dividend" as per the Income Tax Act (R.C.S. (1985), Canada). During the second quarter of 2023, Cascades purchased no common shares for cancellation.

2023 Second Quarter Results Conference Call Details
Management will discuss the 2023 second quarter financial results during a conference call today at 9:00 a.m. EDT. The call can be accessed by dialing 1-888-390-0620 (international 1-416-764-8651). The conference call, including the investor presentation, will be broadcast live on the Cascades website (www.cascades.com) under the "Investors" section. A replay of the call will be available on the Cascades website and may also be accessed by phone until September 3, 2023 by dialing 1-888-390-0541 (international 1-416-764-8677), access code 259981.

Founded in 1964, Cascades offers sustainable, innovative and value-added packaging, hygiene and recovery solutions. The company employs approximately 10,000 women and men across a network of close to 80 facilities in North America. Driven by its participative management, half a century of experience in recycling, and continuous research and development efforts, Cascades continues to provide innovative products that customers have come to rely on, while contributing to the well-being of people, communities and the entire planet. Cascades' shares trade on the Toronto Stock Exchange under the ticker symbol CAS. Certain statements in this release, including statements regarding future results and performance, are forward-looking statements based on current expectations. The accuracy of such statements is subject to a number of risks, uncertainties and assumptions that may cause actual results to differ materially from those projected, including, but not limited to, the effect of general economic conditions, decreases in demand for the Corporation's products, increases in raw material costs, fluctuations in selling prices and adverse changes in general market and industry conditions and other factors.

CONSOLIDATED BALANCE SHEETS

(in millions of Canadian dollars) (unaudited)

June 30,
2023

December 31,
2022

Assets

Current assets

Cash and cash equivalents

41

102

Accounts receivable

537

556

Current income tax assets

11

11

Inventories

611

587

Current portion of financial assets

2

9

1,202

1,265

Long-term assets

Investments in associates and joint ventures

92

94

Property, plant and equipment

2,847

2,945

Intangible assets with finite useful life

63

73

Financial assets

1

4

Other assets

73

70

Deferred income tax assets

152

114

Goodwill and other intangible assets with indefinite useful life

482

488

4,912

5,053

Liabilities and Equity

Current liabilities

Bank loans and advances

4

3

Trade and other payables

634

746

Current income tax liabilities

4

4

Current portion of long-term debt

75

134

Current portion of provisions for contingencies and charges

8

8

Current portion of financial liabilities and other liabilities

22

22

747

917

Long-term liabilities

Long-term debt

2,038

1,931

Provisions for contingencies and charges

41

41

Financial liabilities

7

7

Other liabilities

95

97

Deferred income tax liabilities

145

132

3,073

3,125

Equity

Capital stock

613

611

Contributed surplus

14

14

Retained earnings

1,138

1,212

Accumulated other comprehensive income

14

34

Equity attributable to Shareholders

1,779

1,871

Non-controlling interests

60

57

Total equity

1,839

1,928

4,912

5,053


CONSOLIDATED STATEMENTS OF EARNINGS (LOSS)

For the 3-month periods
ended June 30,

For the 6-month periods
ended June 30,

(in millions of Canadian dollars, except per common share amounts and number of
common shares) (unaudited)

2023

2022

2023

2022

Sales

1,168

1,119

2,302

2,157

Supply chain and logistic

690

713

1,353

1,380

Wages and employee benefits expenses

270

250

543

491

Depreciation and amortization

68

63

130

123

Maintenance and repair

60

50

118

106

Other

7

15

13

31

Impairment charges

2

—

154

—

Gain on acquisitions, disposals and others

—

(4)

(2)

(10)

Restructuring costs

6

—

7

1

Unrealized loss on derivative financial instruments

1

—

2

7

Operating income (loss)

64

32

(16)

28

Financing expense

31

21

54

36

Share of results of associates and joint ventures

(3)

(6)

(15)

(10)

Earnings (loss) before income taxes

36

17

(55)

2

Provision for (recovery of) income taxes

9

3

(15)

(1)

Net earnings (loss) including non-controlling interests for the period

27

14

(40)

3

Net earnings attributable to non-controlling interests

5

4

13

8

Net earnings (loss) attributable to Shareholders for the period

22

10

(53)

(5)

Net earnings (loss) per common share

Basic

$0.22

$0.10

($0.53)

($0.05)

Diluted

$0.22

$0.10

($0.53)

($0.05)

Weighted average basic number of common shares outstanding

100,447,357

100,588,470

100,404,729

100,705,048

Weighted average number of diluted common shares

100,860,684

101,083,826

100,781,402

101,344,843


CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)

For the 3-month periods
ended June 30,

For the 6-month periods
ended June 30,

(in millions of Canadian dollars) (unaudited)

2023

2022

2023

2022

Net earnings (loss) including non-controlling interests for the period

27

14

(40)

3

Other comprehensive income (loss)

Items that may be reclassified subsequently to earnings

Translation adjustments

Change in foreign currency translation of foreign subsidiaries

(22)

32

(24)

21

Change in foreign currency translation related to net investment hedging activities

8

(9)

9

(6)

Cash flow hedges

Change in fair value of commodity derivative financial instruments

1

1

(5)

7

Recovery of (provision for) income taxes

(1)

1

—

(1)

(14)

25

(20)

21

Items that are not released to earnings

Actuarial gain on employee future benefits

2

12

3

31

Provision for income taxes

(1)

(3)

(1)

(8)

1

9

2

23

Other comprehensive income (loss)

(13)

34

(18)

44

Comprehensive income (loss) including non-controlling interests for the period

14

48

(58)

47

Comprehensive income attributable to non-controlling interests for the period

5

5

13

9

Comprehensive income (loss) attributable to Shareholders for the period

9

43

(71)

38


CONSOLIDATED STATEMENTS OF EQUITY

For the 6-month period ended June 30, 2023

(in millions of Canadian dollars)
(unaudited)

CAPITAL STOCK

CONTRIBUTED
SURPLUS

RETAINED
EARNINGS

ACCUMULATED
OTHER
COMPREHENSIVE
INCOME

TOTAL EQUITY
ATTRIBUTABLE TO
SHAREHOLDERS

NON-
CONTROLLING
INTERESTS

TOTAL EQUITY

Balance - Beginning of period

611

14

1,212

34

1,871

57

1,928